Aurinia (Canada) received a Zacks upgrade driven by an upward trend in its earnings estimates.
2 reports, 2 independent
Updated Aug 5
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aurinia (Canada) received a Zacks upgrade driven by an upward trend in its earnings estimates.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Aurinia received a Zacks upgrade based on positive earnings estimate revisions.1 source
Aurinia's revenue growth underperforms industry expectations.1 source
Keep exploring
The entities involved
-
Aurinia (Canada)
company in Victoria, Canada
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksAurinia (AUPH) Upgraded to Buy: Here's What You Should Know Investors might want to bet on Aurinia Pharmaceuticals (AUPH), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade prim
- Simply Wall St.Aurinia Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations Revenue: US$70.0m (up 22% from 2Q 2024). Net income: US$21.5m (up by US$20.8m from 2Q 2024). Profit margin: 31% (up from 1.3%